First study of EMB-07 for advanced cancers or lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This Phase 1 trial tests EMB-07, a new treatment, in people with advanced or hard-to-treat solid tumors or certain relapsed/refractory lymphomas. The goal is to find a safe dose and learn whether it can shrink tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older and able to sign informed consent and follow trial visits
- Your cancer type must match the study list (specific solid tumors or specific lymphomas)
- Your cancer must be advanced and not removable by surgery, or have returned/not responded to prior treatment
- You must have measurable disease on scans (or, for some CLL/SLL cases, specific abnormal cells in blood)
- You must provide a tumor tissue sample from the past (within 2 years) or agree to a new biopsy
- Your body function tests must be adequate and you should have recovered from side effects of prior cancer treatment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study tests PEP07, a drug that blocks a cancer signal pathway (Checkpoint Kinase 1). It aims to see how well it works and how safely it can be given to people with certain advanced relapsed or refractory blood cancers.
This trial tests a new combination treatment for people with aggressive B-cell non-Hodgkin lymphoma, including those with relapsed/refractory disease or newly diagnosed high-risk cases. It aims to see if EMB-07 combined with other drugs is safe and effective.
This trial tests a new drug, EMB-01, in people with advanced left-sided colorectal cancer that has spread or cannot be removed. It may help if standard treatments have stopped working or caused side effects.
This trial tests a new drug called EMB-01 combined with standard chemotherapy to treat colorectal cancer that cannot be surgically removed or has spread to other parts of the body. The goal is to see if this combination helps slow or shrink the cancer.
This is a first-time-in-humans study testing a new drug called EMB-15 for patients with advanced cancers that have spread or cannot be surgically removed. The drug targets proteins called ALPP/ALPG, which may help your immune system fight cancer cells.
This early-phase trial studies EMB-01 in people with advanced or metastatic gastrointestinal cancers to see how well it works and how safe it is. To join, your tumor’s DNA or protein pattern (especially EGFR or cMET) must match specific lab results, and you must have tried standard treatments.
Hear when a new Advanced/Metastatic Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.